JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265746

Human HMGN4 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

HMGN4 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 2 and 31 bp deletion in exon 2.

View Alternative Names

HMG17L3, HMGN4_HUMAN, High mobility group (nonhistone chromosomal) protein 17 like 3, High mobility group nucleosomal binding domain 4, High mobility group nucleosome-binding domain-containing protein 4, High mobility group protein 17 like 3, High mobility group protein N4, MGC5145, NHC, Non-histone chromosomal protein, Non-histone chromosomal protein HMG-17-like 3

2 Images
Sanger Sequencing - Human HMGN4 knockout HeLa cell line (AB265746)
  • Sanger seq

Unknown

Sanger Sequencing - Human HMGN4 knockout HeLa cell line (AB265746)

Allele-1 : 31 bp deletion in exon 2.

Sanger Sequencing - Human HMGN4 knockout HeLa cell line (AB265746)
  • Sanger seq

Unknown

Sanger Sequencing - Human HMGN4 knockout HeLa cell line (AB265746)

Allele-2 : 1 bp insertion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 2 and 31 bp deletion in exon 2

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265746-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265746 Human HMGN4 knockout HeLa cell line", "number":"AB265746-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265746-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265746 Human HMGN4 knockout HeLa cell line", "number":"AB265746-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
HMGN4
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

HMGN4 also known as High Mobility Group Nucleosome Binding Domain 4 is a chromosomal protein with an approximate mass of 12 kDa. This protein functions mechanically by binding to nucleosomes altering the chromatin structure and influencing gene expression. It is expressed in various tissues with higher levels found in the brain and testis. HMGN4 plays roles in regulating the dynamics of chromatin impacting accessibility and stability of DNA.
Biological function summary

HMGN4 modulates transcriptional activity by altering the chromatin compaction state not working as a part of a complex. It influences how genes are turned on or off impacting cellular processes such as differentiation and proliferation. This modulation occurs through its interaction with nucleosomes positioning it as an important factor in the control of gene regulatory mechanisms across different cell types.

Pathways

Researchers study HMGN4 to understand its involvement in transcriptional regulation and DNA repair pathways. These pathways guide critical cellular activities affecting how cells respond to damage and manage genetic information. HMGN4 interacts with proteins like histone H1 an important player in facilitating chromatin remodeling which supports effective gene regulation and maintains genomic integrity.

Researchers associate HMGN4 with certain types of cancer and neurological disorders. Aberrant expression levels of HMGN4 have links to tumor progression as altered chromatin states may lead to deregulation of oncogenes. The protein connects to Alzheimer's disease through its influence on neuronal gene expression implicating interactions with tau proteins. These associations highlight HMGN4 as a potential target for therapeutic interventions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com